DAYTONA BEACH, FL--(Marketwire - Nov 13, 2012) - Quture (OTCQB: QUTR) announced today the new hire of Paul L. Rudisill as the company's first Chief Business Development Officer. Rudisill is a global healthcare leader, known for his strategic and visionary strength. With more than 30 years as a clinician and healthcare executive, Rudisill's goal is to decrease the delta between life's longevity and one's quality of life. Rudisill has held leadership positions with large integrated delivery systems (e.g. Presbyterian Healthcare System and Methodist Health Systems), provider groups/MSOs and technology companies.
Quture is now engaged in marketing and sales of its QualOptima Analytics and Connectivity System. Rudisill has already begun working with his extensive contacts, dramatically adding to the company's prospects. However, his role and responsibilities at Quture go well beyond marketing and sales and channel distribution to strategic planning and implementation and continued product design, functionality and development. He is expected to play a significant role in plans for future mergers, acquisitions and international growth.
Rudisill's international experience and leadership is a major factor in his selection by Quture for this position. Rudisill was the Senior Executive for EDS' Global Healthcare Business Unit where he was responsible for developing EDS' strategic direction by refocusing on clinical outcomes and providing world-class service for the health industry. Rudisill has served as a consultant to many public and private healthcare entities both nationally and internationally such as the New Zealand Ministry of Health, South Australian Health Commission and other organizations in Asia/ Pacific, Latin America, Canada and the European Union. As an example of his success, Rudisill's vision created an annual savings of $21 million for one delivery enterprise in New Zealand, while opening up access and quantifiably improving care.
"Despite Quture's significant first to market advantage, we find ourselves in a continuous and competitive growing market for healthcare analytics," said Landon Feazell, Chairman and CEO of Quture. "Paul has previous significant involvement with the development of Quture, and we know his immense breadth and depth of insight, knowledge and global experience to implement the strategic plans of Quture. His passion for transforming data to information and information to knowledge make him an extraordinary addition to our Management Team. His leadership in areas such as predictive modeling and mobile phone applications will be invaluable to the future of Quture."
After his career with EDS, Rudisill founded The Healthcare Intellect Group (HIG) in 2000 where he focused on globalizing small and emerging healthcare companies using his extensive relations worldwide. HIG's clients ranged from healthcare professional service companies to financial/clinical technology companies. Rudisill helped to expand companies, not only in the depth of clients, but in the extent of product offerings related to clinical process and outcomes management. He is a hands-on executive with extensive experience in the healthcare industry, especially in the areas of enterprise planning/re-engineering, leadership, financial growth, use of technologies and prospective outcomes.
"I selected Quture from many other opportunities because I am convinced that this company, its products, strategies, and its vision have the best opportunity to dominate the global market and to achieve my professional goals for transforming health and health care," said Rudisill. "With the elections over and knowing that the Affordable Care Act will stand, the opportunities for Quture are even greater. I firmly believe that the key to improving healthcare, and subsequently lowering costs, is through the careful application of technology. Improving clinical quality is about focusing on processes and looking at how they could be improved and streamlined. We have to be forward thinking and the only way to have a real impact is through technology that will take us into the future. We need to evolve from healthcare silo based processes, to a foundation of an Outcomes Prospective Continuum with decisions supported from Knowledge rather than retrospective Data or Concurrent Information."
ABOUT QUTURE INTERNATIONAL, INC. (www.quture.com)
Quture International, Inc. (QUTR) is the proven and experienced performance and outcomes analytics company in the United States. The vision of Quture is to connect all constituents in the global health and health care community to clinically and financially focused and sound data transformed through analytics to knowledge that empowers data-driven decisions for results-driven success. As a "Breakthrough" Application Partner of InterSystems Corporation, Quture's technology for capturing, integrating and aggregating data on the InterSystems Enterprise platform is unequalled. The Company's unique product QualOptima develops a second generation CLINICAL database implementing Quture's core competence of clinical content with evidence-based metrics developed for more than 35 years. QualOptima empowers clinical performance enhancement to achieve optimal patient outcomes. Quture's brand is centered on the value proposition of trust, transparency and independence. As the free enterprise solution to improving health and healthcare while reducing costs, Quture is positioned to become the leading clinical knowledge company in the world. Quture International is a Nevada corporation trading under the symbol QUTR.
This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern, adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs, customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law. There is no assurance that a definitive agreement will be completed.